Biomarker ID | 664 |
PMID | 21626193 |
Year | 2011 |
Biomarker | Dihyroxybutanoic acid + Pyrimidine + Xylonic acid + Xylopyranose + Ribofuranoside |
Biomarker Basis | Expression Based |
Biomolecule | Metabolites |
Source | Urine |
Subjects | Humans |
Regulation | Upregulated in PCA: (Dihyroxybutanoic acid, Xylonic acid); Downregulated in PCA: (Pyrimidine, Xylopyranose, Ribofuranoside) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | PCa Vs Non Cancerous (healthy+BPH) |
Type of Biomarker | Diagnostic |
Cohort | 20 patients with Prostate Cancer alog woth 8 patients wth BPH and 20 healthy controls were used for this study. |
Senstivity | NA |
Specificity | NA |
AUC | 0.825 |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | Isotope dilution gas chromatography/ mass spectrometry (ID GC/MS) |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |